| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing toxicity risk when designing and selecting compounds in early drug discovery
|
Segall, Matthew D.
|
|
2014
|
19 |
5 |
p. 688-693
6 p.
|
artikel
|
| 2 |
Alternative carriers in dry powder inhaler formulations
|
Rahimpour, Yahya
|
|
2014
|
19 |
5 |
p. 618-626
9 p.
|
artikel
|
| 3 |
Are there meaningful biomarkers of treatment response for depression?
|
Breitenstein, Barbara
|
|
2014
|
19 |
5 |
p. 539-561
23 p.
|
artikel
|
| 4 |
Binucleation of cardiomyocytes: the transition from a proliferative to a terminally differentiated state
|
Paradis, Alexandra N.
|
|
2014
|
19 |
5 |
p. 602-609
8 p.
|
artikel
|
| 5 |
Contents page 1
|
|
|
2014
|
19 |
5 |
p. i-
1 p.
|
artikel
|
| 6 |
Contents page 2
|
|
|
2014
|
19 |
5 |
p. iii-
1 p.
|
artikel
|
| 7 |
Current status and future prospects of toxicogenomics in drug discovery
|
Khan, Saifur R.
|
|
2014
|
19 |
5 |
p. 562-578
17 p.
|
artikel
|
| 8 |
d-Arginine as a neuroprotective amino acid: promising outcomes for neurological diseases
|
Canteros, M. Griselda
|
|
2014
|
19 |
5 |
p. 627-636
10 p.
|
artikel
|
| 9 |
Drug name recognition in biomedical texts: a machine-learning-based method
|
He, Linna
|
|
2014
|
19 |
5 |
p. 610-617
8 p.
|
artikel
|
| 10 |
Extemporaneously prepared controlled release formulations for accelerating the early phase development of drug candidates
|
Thombre, Avinash G.
|
|
2014
|
19 |
5 |
p. 694-700
7 p.
|
artikel
|
| 11 |
Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome
|
Zhang, Jun
|
|
2014
|
19 |
5 |
p. 579-589
11 p.
|
artikel
|
| 12 |
Financing drug discovery for orphan diseases
|
Fagnan, David E.
|
|
2014
|
19 |
5 |
p. 533-538
6 p.
|
artikel
|
| 13 |
Finding the rules for successful drug optimisation
|
Yusof, Iskander
|
|
2014
|
19 |
5 |
p. 680-687
8 p.
|
artikel
|
| 14 |
GPR120 agonism as a countermeasure against metabolic diseases
|
Cornall, Lauren M.
|
|
2014
|
19 |
5 |
p. 670-679
10 p.
|
artikel
|
| 15 |
Immunosuppressive peptides and their therapeutic applications
|
Thell, Kathrin
|
|
2014
|
19 |
5 |
p. 645-653
9 p.
|
artikel
|
| 16 |
Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies
|
Chapman, Kathryn
|
|
2014
|
19 |
5 |
p. 528-532
5 p.
|
artikel
|
| 17 |
Recombinant protein production in bacterial hosts
|
Overton, Tim W.
|
|
2014
|
19 |
5 |
p. 590-601
12 p.
|
artikel
|
| 18 |
Restoring trust in the pharmaceutical sector on the basis of the SSRI case
|
Hernandez, Juan Francisco
|
|
2014
|
19 |
5 |
p. 523-527
5 p.
|
artikel
|
| 19 |
Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders
|
Szabadi, Elemer
|
|
2014
|
19 |
5 |
p. 701-708
8 p.
|
artikel
|
| 20 |
Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases
|
Dekker, Frank J.
|
|
2014
|
19 |
5 |
p. 654-660
7 p.
|
artikel
|
| 21 |
Therapeutic perspectives of Eph–ephrin system modulation
|
Tognolini, Massimiliano
|
|
2014
|
19 |
5 |
p. 661-669
9 p.
|
artikel
|
| 22 |
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
|
Jin, Guangxu
|
|
2014
|
19 |
5 |
p. 637-644
8 p.
|
artikel
|
Tijdschrift beschrijving